Market Size (2015)
2015
$797.90M
Vertical: HealthcareBase Year: 201711 Sections
Market Size (2015)
2015
$797.90M
Projected (2023)
2023
$1.11B
CAGR (2015–2023)
4.2%
4.2%Key Players
109+
The global prils market includes active pharmaceutical ingredients (API). APIs are biologically active ingredients or substances which are an important part of any medicine. There are different APIs available with different properties and are used accordingly by the pharmaceutical, biotech, and nutritional industry to develop new products. The key factors responsible for driving the market are increasing prevalence of heart diseases, hypertension and kidney related problems, rising geriatric population, growing importance of generic drugs, and also the overall uptake of the biopharmaceuticals industry. Nevertheless, factors such as unfavorable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures hamper the market growth.
The Prils Market market is projected to grow at a CAGR of 4.2% from 2015 to 2023.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe scope of the global prils market study includes the market size analysis and a detailed analysis of the manufacturers’ products and strategies. The market has been segmented based on type, application, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2017
Forecast Period
2017 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansBargaining Power of Suppliers
The suppliers in the global prils industry are the developers and manufacturers of API molecules. Bargaining power of suppliers in the prils market is low to moderate. The number of suppliers in the market is high which gives plenty of options to drug manufacturers for material sourcing which is required for the production of various drugs, thus leaving suppliers with medium bargaining power. Switching cost of these suppliers is also high as suppliers tend to enter into long-term associations with the pharmaceutical manufacturers. However, the North American countries are consisting of a large number of suppliers which offer these molecules products at a relatively less price. Difficulties in manufacturing APIs such as peptides, sex hormones, and steroids give the bargaining power to suppliers. However, in the case of generic APIs, such thing is not applicable. Due to this reason of medium bargaining power of suppliers, the profit potential of the global prils industry gets condensed.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global prils market. The market has a large number of buyers comprising of various small and large molecules API manufacturing companies. The buyers of small molecule API globally are moderately inclined towards small molecule API manufacturers. Moreover, the buyers can exert moderate pressure on the manufacturers as they already provide high-quality products and services. Generic drugs offer a cost-effective alternative to drug innovators and significant savings to the customers. Biosimilars offer significant cost savings for insurance companies in India. Hence with the high level of products and services provided by the API manufacturers the bargaining power of suppliers tend to be moderate.
Threat of New Entrants
The threat of new entrants is moderate in the prils market. Any manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. The prils market is also characterized by a reasonable degree of brand loyalty where establishing a brand name is difficult for newcomers. Moreover, increasing geriatric population and funding are influencing many of the start-ups to take a keen interest in the field of research and development. The introduction of new drugs requires a clinical trial that demands long duration and huge capital investment. However, the cost involved in R&D is comparatively high which does not comfort the new entrants to enter the market easily.
Threat of Substitutes
The threat of substitutes in the prils market is moderate to high with the only substitute is in the form of large molecules. Buyer propensity to substitute is less due to the low availability of substitutes in this market. In addition, the high degree of switching cost minimizes the threat of substitutes. In addition to this, the introduction of generic drugs and increasing competition in the market has increased the availability of the products. Thus, the high degree of switching cost increases the threat of substitutes.
Intense Rivalry
The degree of competition in the prils market is moderate to high. The reserved degree of product differentiation among existing players increases the intensity of rivalry in the market. API manufacturing companies are trying to develop less expensive products to make these products more affordable in developing regions. To overcome the competition, players are engaged in developing a process to lower their manufacturing cost.
Moreover, the players are also developing advanced products for differentiating their brand from their rivals. Developing a new API molecule needs approval which is a time consuming and expensive process as the existing drugs are less effective and unsafe. However, the increasing government support and availability of funding have encouraged many new start-ups. To compete with multinational players, new and small companies are reducing the cost of their products.
Market estimates by geography (2023)
InsightNorth America leads with $377.10M by 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $48.00M | $53.20M | $59.10M | 2.6% | 5% |
| North America | $263.10M | $314.20M | $377.10M | 4.6% | 34% |
| Asia Pacific | $179.90M | $213.60M | $254.80M | 4.4% | 23% |
| Europe | $260.90M | $307.40M | $364.00M | 4.3% | 33% |
| South America | $46.00M | $51.30M | $57.20M | 2.8% | 5% |
| Total | $797.90M | $939.70M | $1.11B | 4.2% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$1.55B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Quinapril | $884.40M | 4.2% | 60% |
| Cilazapril | $304.80M | 4.2% | 67% |
| Ramipril | $242.50M | 4.2% | 89% |
| Benazepril | $114.60M | 4.2% | 67% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Prils Market covering market dynamics, competitive landscape, and strategic outlook.
The Prils Market market is projected to reach $1.11B by 2023, growing at 4.2% CAGR. The Quinapril segment holds the largest share.
The global prils market includes active pharmaceutical ingredients (APIs) ingredients. APIs are biologically active ingredients or substances which are important the part of any medicine. There are different APIs available with different properties, and they are used by pharmaceutical, biotech, and nutritional industries accordingly to develop new products. The key factors responsible for driving the market are increasing prevalence of heart diseases, hypertension and kidney related problems, rising geriatric population, growing importance of generic drugs, and also the overall uptake of the biopharmaceuticals industry.
However, factors such as unfavorable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures hamper the market growth.
The increasing prevalence of various chronic diseases has served as a good platform for manufacturers. Many types of active pharmaceutical ingredients are available in the market. However, many of them have different side-effects, and thus, there are a number of opportunities for manufacturers to develop new drugs. Many drugs are not prescribed to patients suffering from hypernatremia and other diseases. Beside this, there are huge opportunities for the development of the market in developing countries. Benazepril, cilazapril, quinapril, and ramipril are used for the treatment of heart-related diseases and hypertension.
Thus, the development of new drugs can pose tons of opportunities for the growth of the market.
There are different regulatory authorities such as the World Health Organization (WHO), the US Food and Drug Administration, and many more. These organizations have developed some guidelines which have to be followed by drug manufacturing companies. Regulatory compliance is considered to be the primary hurdle challenging the API market at every point. The FDA is regulating the quality assurance in the US and other regions.
Besides, Indian API manufacturers are investing in complying with the US FDA regulations for obtaining contracts from US-based companies. Although these regulations are serving to improve and maintain the quality of drugs, they are also curbing the growth of the API manufacturing market especially in developing regions of Asia-Pacific. These high regulations make the procedure more tedious and also increase the cost of production.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 109 companies operating in the Prils Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Merck KGaA
Company Headquarters: Darmstadt, Germany Founded: 1668 Workforce: ~60,348 Company Working: Merck KGaA (Merck) is a pharmaceutical company that offers a varied range of products subgrouped into three segments—healthcare, life sciences, and performance materials. The company delivers innovative health solutions and is dedicated to providing breakthrough solutions and technologies. The company research drugs in the areas of oncology and neurodegenerative as well as autoimmune and inflammatory diseases. It also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for industries such as pharmaceuticals, food, cosmetics, packaging, and coatings. It has expanded its global footprint through several mergers and acquisitions, such as the acquisition of Millipore and Sigma-Aldrich. The company is distributing its products in the following countries: China, India, Japan, Australia, Israel, United Arab Emirates, South Korea, Denmark, Italy, Netherlands, Spain, United Kingdom, Switzerland, Sweden, Argentina, Brazil, Canada, US, New Zealand among others.
Novartis AG
Company Headquarters: Basel, Switzerland Founded: 1996 Workforce: ~126,000 Company Working: Novartis AG (Novartis) was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its preceding companies have been known to develop innovative products which can be traced back to over 250 years. The company focuses on the development and marketing of products that contribute to human progress through advances in science and health. It provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory disease areas. Its Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, dermatology, central nervous system (CNS), gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas, among others. It also provides active pharmaceutical ingredients (API) and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.
Canagen Pharmaceuticals Inc.
Company Headquarters: Richmond, British Columbia (US) Founded: 2001 Workforce: 10 Company Working: Canagen Pharmaceuticals Inc. is a subsidiary of the Fazio Group of Companies. Canagen Pharmaceuticals Inc. is an innovative generic pharmaceuticals company involved in the manufacturing of generic pharmaceutical products, active pharmaceutical ingredients (API), and over-the-counter (OTC) medication. The company has its in-house research and development facility to develop and commercialize innovative drugs for the treatment of various critical diseases such as oncology, cardiovascular, dementia, and anti-viral infections. Canagen Pharmaceuticals Inc. has its pharmaceutical manufacturing factories in India, China, Canada, and Russia and sales and distribution offices in the US, India, China, Hong Kong, and Cyprus.
Manus Aktteva Biopharma LLP
Company Headquarters: Ahmedabad, Gujarat, India Founded: 1997 Company Working: Manus Aktteva Biopharma LLP is a privately held company which is into manufacturing and marketing of pharmaceutical raw materials to pharmaceuticals, nutraceuticals, specialty chemicals, and biotechnology companies. It operates in business segments, namely, API, intermediates, and other products. It offers products and services to institutional and corporate customers and exports its products in more than 50 countries. The company has a strong network in China, India, and European countries. It is a trusted raw material supplier in the market and has the ISO 9001:2008 certification.
Sun Pharmaceutical Industries Ltd
Company Headquarters: Mumbai, India Founded: 1983 Workforce: ~30,000 Company Working: Sun Pharmaceutical Industries Ltd (Sun Pharma) is one of India’s top pharmaceutical companies. It is the world’s fourth-largest generic pharmaceutical company. The company has vertically integrated businesses, high economies of scale, and a highly-skilled team. Sun Pharma delivers high-quality and reasonable medicines trusted by customers in over 150 countries globally, such as the US, Canada, Brazil, Germany, France, Russia, Japan, and South Africa. It also has a specialty products portfolio which contains ten specialty products, out of which five are in the market, three are likely to be commercialized soon, and two are awaiting USFDA approvals. It has its products in various leading therapeutic areas such as diabetes, oncology, pain, autoimmune diseases, respiratory diseases, antibiotics and vaccines, cardiovascular, HIV, mental health, and antivirals. Sun Pharma sells its duloxetine and atorvastatin products under the brand name AZTOR.
F. Hoffmann-La Roche
Company Headquarters: Basel, Switzerland Founded: 1896 Workforce: 91,700 Company Working: F. Hoffmann-La Roche is a biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The company is dedicated to developing innovative diagnostic tests and medicines. The products offered by the company help in tapping the world’s two third of all the diseases which are either still not treated effectively or not treated at all. It operates in North America, Europe, South America, Africa, and Asia-Oceania.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Prils Market